-
V.
Hirsh
(2018)
Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
Therapeutic Advances in Medical Oncology, 10
-
Youjin
Kim,
Se-Hoon
Lee,
J.
Ahn,
M.
Ahn,
Keunchil
Park,
Jong-Mu
Sun
(2018)
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Cancer Research and Treatment : Official Journal of Korean Cancer Association, 51
-
S
Khozin,
GM
Blumenthal,
R.
Pazdur
(2017)
Real-world data for clinical evidence generation in
oncology
J Natl Cancer Inst, 109
-
B.
Halmos,
E.
Tan,
M.
Lee,
P.
Foucher,
T.
Hsia,
M.
Hochmair,
F.
Griesinger,
T.
Hida,
Edward
Kim,
B.
Melosky,
A.
Maerten,
E.
Costa
(2018)
Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm+) advanced NSCLC.
Journal of Clinical Oncology, 36
-
Sheng-Kai
Liang,
Meng-Rui
Lee,
W.
Liao,
Chao-Chi
Ho,
J.
Ko,
J.
Shih
(2018)
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study
Oncotarget, 9
-
L.
Sequist,
J.
Yang,
N.
Yamamoto,
K.
O'Byrne,
V.
Hirsh,
T.
Mok,
Sarayut
Geater,
S.
Orlov,
C.
Tsai,
M.
Boyer,
W.
Su,
J.
Bennouna,
T.
Kato,
V.
Gorbunova,
K.
Lee,
R.
Shah,
D.
Massey,
V.
Zazulina,
M.
Shahidi,
M.
Schuler
(2013)
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 27
-
P.
Jänne,
J.
Yang,
Dong-Wan
Kim,
D.
Planchard,
Y.
Ohe,
S.
Ramalingam,
M.
Ahn,
Sang-We
Kim,
W.
Su,
L.
Horn,
D.
Haggstrom,
E.
Felip,
Joo‐Hang
Kim,
P.
Frewer,
M.
Cantarini,
K.
Brown,
P.
Dickinson,
S.
Ghiorghiu,
M.
Ranson
(2015)
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
The New England journal of medicine, 372 18
-
Yen-Ting
Lin,
Jin-Shing
Chen,
W.
Liao,
Chao-Chi
Ho,
Chia-Lin
Hsu,
Ching-Yao
Yang,
Kuan-Yu
Chen,
Jih-hsiang
Lee,
Zhong‐Zhe
Lin,
J.
Shih,
J.
Yang,
Chong-Jen
Yu
(2019)
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations
International Journal of Cancer, 144
-
Subsequent therapies post-afatinib among patients with EGFR mutation-positive NSCLC in LUX-Lung (LL) 3, 6 and 7
-
W.
Tan,
Q.
Ng,
C.
Lim,
E.
Tan,
C.
Toh,
M.
Ang,
R.
Kanesvaran,
Amit
Jain,
D.
Tan,
D.
Lim
(2018)
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
BMC Cancer, 18
-
Shirong
Zhang,
Lucheng
Zhu,
Yanping
Jiang,
Jing
Zhang,
Ru-jun
Xu,
Yasi
Xu,
B.
Xia,
Shenglin
Ma
(2016)
Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice
, 38
-
P.
Ballard,
J.
Yates,
Zhenfan
Yang,
Dong-Wan
Kim,
J.
Yang,
M.
Cantarini,
K.
Pickup,
Angela
Jordan,
Mike
Hickey,
Matthew
Grist,
Matthew
Box,
P.
Johnström,
K.
Varnäs,
J.
Malmquist,
K.
Thress,
P.
Jänne,
D.
Cross
(2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Clinical Cancer Research, 22
-
K.
Ito,
K.
Murotani,
A.
Kubo,
E.
Kunii,
H.
Taniguchi,
J.
Shindo,
K.
Asada,
K.
Imaizumi,
K.
Tanaka,
N.
Inui,
M.
Okuno,
O.
Hataji,
S.
Hayai,
T.
Abe,
T.
Kimura,
T.
Tsuda,
T.
Yamaguchi,
Y.
Oya,
T.
Yoshida,
T.
Hida
(2018)
Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
M.
Schuler,
Yi-long
Wu,
V.
Hirsh,
K.
O'Byrne,
N.
Yamamoto,
T.
Mok,
S.
Popat,
L.
Sequist,
D.
Massey,
V.
Zazulina,
J.
Yang
(2016)
First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Journal of Thoracic Oncology, 11
-
M.
Hochmair
(2018)
Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
Targeted Oncology, 13
-
B
Halmos,
E-H
Tan,
MK
Lee
(2018)
Real-world dose adjustment study of first-line
afatinib in pts with EGFR mutation-positive (EGFRm + ) advanced
NSCLC
J Clin Oncol, 36
-
L.
Sequist,
B.
Waltman,
D.
Dias-Santagata,
S.
Digumarthy,
Alexa
Turke,
P.
Fidias,
K.
Bergethon,
A.
Shaw,
S.
Gettinger,
A.
Cosper,
S.
Akhavanfard,
R.
Heist,
J.
Temel,
J.
Christensen,
J.
Wain,
T.
Lynch,
Kathy
Vernovsky,
E.
Mark,
M.
Lanuti,
A.
Iafrate,
M.
Mino‐Kenudson,
J.
Engelman
(2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine, 3
-
Y
Wu,
H
Tu,
J
Feng
(2018)
P1.01–98 A phase IIIb trial of afatinib in EGFRm
+ NSCLC: analyses of outcomes in patients with brain metastases or dose
reductions
J Thorac Oncol, 13
-
M.
Hochmair,
A.
Morabito,
D.
Hao,
Cheng-Ta
Yang,
R.
Soo,
J.
Yang,
R.
Gucalp,
B.
Halmos,
Lara
Wang,
A.
Golembesky,
A.
Märten,
T.
Čufer
(2018)
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future oncology, 14 27
-
MJ
Hochmair,
A
Morabito,
D
Hao
Sequential treatment with afatinib and
osimertinib in patients with EGFR mutation-positive non-small-cell lung
cancer: an observational study
Future
Oncol
-
Chih-Jen
Yang,
M.
Tsai,
J.
Hung,
Mei‐Hsuan
Lee,
Ying‑Ming
Tsai,
Yu-Chen
Tsai,
J.
Hsu,
Ta‐Chih
Liu,
Ming-Shyan
Huang,
I.
Chong
(2017)
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
BMC Pharmacology & Toxicology, 18
-
Zhe
Yang,
N.
Yang,
Q.
Ou,
Y.
Xiang,
T.
Jiang,
Xue
Wu,
H.
Bao,
X.
Tong,
Xiaonan
Wang,
Y.
Shao,
Yunpeng
Liu,
Yan
Wang,
Caicun
Zhou
(2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
Clinical Cancer Research, 24
-
K.
Arbour,
M.
Kris,
Gregory
Riely,
A.
Ni,
K.
Beal,
M.
Daras,
S.
Hayes,
R.
Young,
C.
Rodriguez,
Linda
Ahn,
W.
Pao,
H.
Yu
(2018)
Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
Cancer, 124
-
N.
Girard
(2018)
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Future oncology, 14 11
-
Suresh
Ramalingam,
Y.
Cheng,
C.
Zhou,
Yuichiro
Ohe,
Fumio
Imamura,
B.
Cho,
M.-C.
Lin,
M.
Majem,
R.
Shah,
Y.
Rukazenkov,
A.
Todd,
A.
Markovets,
J.
Barrett,
J.
Chmielecki,
J.
Gray
(2018)
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.
Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
G.
Oxnard,
Yuebi
Hu,
K.
Mileham,
H.
Husain,
D.
Costa,
P.
Tracy,
N.
Feeney,
L.
Sholl,
S.
Dahlberg,
A.
Redig,
D.
Kwiatkowski,
M.
Rabin,
C.
Paweletz,
K.
Thress,
P.
Jänne
(2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology, 4
-
J.
Soria,
Y.
Ohe,
J.
Vansteenkiste,
T.
Reungwetwattana,
B.
Chewaskulyong,
K.
Lee,
A.
Dechaphunkul,
F.
Imamura,
N.
Nogami,
T.
Kurata,
I.
Okamoto,
Caicun
Zhou,
B.
Cho,
Ying
Cheng,
E.
Cho,
P.
Voon,
D.
Planchard,
Wu‐Chou
Su,
J.
Gray,
S.
Lee,
R.
Hodge,
M.
Marotti,
Y.
Rukazenkov,
S.
Ramalingam
(2018)
Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
The New England Journal of Medicine, 378
-
G.
O’Kane,
P.
Bradbury,
R.
Feld,
N.
Leighl,
Geoffrey
Liu,
K.
Pisters,
S.
Kamel‐Reid,
M.
Tsao,
F.
Shepherd
(2017)
Uncommon EGFR mutations in advanced non-small cell lung cancer.
Lung cancer, 109
-
B.
Melosky,
V.
Hirsh
(2014)
Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
Frontiers in Oncology, 4
-
Yi-long
Wu,
L.
Sequist,
E.
Tan,
Sarayut
Geater,
S.
Orlov,
Li
Zhang,
K.
Lee,
C.
Tsai,
T.
Kato,
C.
Barrios,
M.
Schuler,
V.
Hirsh,
N.
Yamamoto,
K.
O'Byrne,
M.
Boyer,
T.
Mok,
B.
Peil,
A.
Märten,
J.
Yang,
L.
Paz-Ares,
Keunchil
Park
(2018)
Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials
Clinical Lung Cancer, 19
-
Kentaro
Tanaka,
K.
Nosaki,
K.
Otsubo,
K.
Azuma,
S.
Sakata,
Hiroshi
Ouchi,
R.
Morinaga,
H.
Wataya,
A.
Fujii,
Noriaki
Nakagaki,
N.
Tsuruta,
M.
Takeshita,
E.
Iwama,
T.
Harada,
Y.
Nakanishi,
I.
Okamoto
(2017)
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
Oncotarget, 8
-
T.
Mitsudomi,
S.
Morita,
Y.
Yatabe,
S.
Negoro,
I.
Okamoto,
J.
Tsurutani,
T.
Seto,
M.
Satouchi,
H.
Tada,
T.
Hirashima,
K.
Asami,
N.
Katakami,
M.
Takada,
H.
Yoshioka,
K.
Shibata,
S.
Kudoh,
E.
Shimizu,
H.
Saito,
S.
Toyooka,
K.
Nakagawa,
M.
Fukuoka
(2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
The Lancet. Oncology, 11 2
-
Chien‐Ying
Liu,
Chih-Liang
Wang,
Shih-Hong
Li,
Ping-Chih
Hsu,
Chih-Hung
Chen,
Ting-Yu
Lin,
C.
Kuo,
Yueh-Fu
Fang,
How-Wen
Ko,
Chih-Teng
Yu,
Tai-Yun
Yang,
Cheng-Ta
Yang
(2017)
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations
Oncotarget, 8
-
Epub ahead of print
-
H.
Yu,
M.
Arcila,
N.
Rekhtman,
C.
Sima,
M.
Zakowski,
W.
Pao,
M.
Kris,
V.
Miller,
M.
Ladanyi,
Gregory
Riely
(2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Clinical Cancer Research, 19
-
R.
Rosell,
E.
Carcereny,
R.
Gervais,
A.
Vergnenègre,
B.
Massutí,
E.
Felip,
R.
Palmero,
R.
García-Gómez,
C.
Pallarés,
J.
Sánchez,
R.
Porta,
M.
Cobo,
P.
Garrido,
F.
Longo,
T.
Morán,
A.
Insa,
F.
Marinis,
R.
Corre,
I.
Bover,
A.
Illiano,
É.
Dansin,
J.
Castro,
M.
Milella,
N.
Reguart,
G.
Altavilla,
U.
Jiménez,
M.
Provencio,
M.
Moreno,
J.
Terrasa,
J.
Muñoz-Langa,
J.
Valdivia,
D.
Isla,
M.
Dómine,
O.
Molinier,
J.
Mazières,
N.
Baize,
R.
García-Campelo,
G.
Robinet,
D.
Rodríguez-Abreu,
G.
López-Vivanco,
V.
Gebbia,
Lioba
Ferrera-Delgado,
P.
Bombaron,
R.
Bernabé,
A.
Bearz,
Á.
Artal,
E.
Cortesi,
C.
Rolfo,
M.
Sánchez-Ronco,
A.
Drozdowskyj,
C.
Queralt,
I.
Aguirre,
J.
Ramírez,
J.
Sánchez,
M.
Molina,
M.
Taron,
L.
Paz-Ares
(2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology, 13 3
-
M
Maemondo,
A
Inoue,
K
Kobayashi
(2010)
Gefitinib or chemotherapy for non-small-cell
lung cancer with mutated EGFR
N Engl J Med, 362
-
K
Ito,
K
Murotani,
A
Kubo
(2018)
Comparative analysis of overall survival using
propensity score between first- and second-generation EGFR-TKI: real world
data of 1354 patients with EGFR mutant NSCLC
Ann
Oncol, 29
-
Y
Kim,
J-M
Sun,
S-H
Lee
(2017)
First-line afatinib for non-small-cell lung
cancer in real-world practice
J Thorac
Oncol, 12
-
Y.
Taniguchi,
A.
Tamiya,
K.
Nakahama,
Yoko
Naoki,
M.
Kanazu,
N.
Omachi,
K.
Okishio,
T.
Kasai,
S.
Atagi
(2017)
Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors.
Oncology letters, 14 6
-
M.
Arcila,
G.
Oxnard,
K.
Nafa,
Gregory
Riely,
S.
Solomon,
M.
Zakowski,
M.
Kris,
W.
Pao,
V.
Miller,
M.
Ladanyi
(2011)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Clinical Cancer Research, 17
-
Suresh
Ramalingam,
Jie
Yang,
Chee
Lee,
T.
Kurata,
Dong-Wan
Kim,
T.
John,
N.
Nogami,
Y.
Ohe,
H.
Mann,
Y.
Rukazenkov,
S.
Ghiorghiu,
Daniel
Stetson,
A.
Markovets,
J.
Barrett,
K.
Thress,
P.
Jänne
(2017)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 9
-
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
-
J
Skřičková,
R
Chloupková,
Z
Bortlíček
(2017)
Characteristics of NSCLC patients treated in
first line treatment with tyrosine kinase inhibitors (TKI) – real data from
the Czech Republic
J Thorac Oncol, 12
-
Shih-Hong
Li,
Chien‐Ying
Liu,
Ping-Chih
Hsu,
Yueh-Fu
Fang,
Chun-Chieh
Wang,
K.
Kao,
Li‐Chuan
Tseng,
Cheng-Ta
Yang
(2018)
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases
Expert Review of Anticancer Therapy, 18
-
L.
Sequist,
Y.
Wu,
M.
Schuler,
T.
Kato,
J.C.
Yang,
Hiroshi
Tanaka,
T.
Hida,
Shun
Lu,
K.
Park,
S.
Laurie,
J.
Bennouna,
D.
Sibilot,
A.
Märten,
B.
Peil,
E.
Ehrnrooth,
N.
Yamamoto,
K.
Nakagawa
(2017)
1349PSubsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
Annals of Oncology, 28
-
Caicun
Zhou,
Yi-long
Wu,
Gongyan
Chen,
Jifeng
Feng,
Xiao‐qing
Liu,
Chang-li
Wang,
Shucai
Zhang,
Jie
Wang,
Songwen
Zhou,
S.
Ren,
Shun
Lu,
Li
Zhang,
Chengping
Hu,
Chunhong
Hu,
Yi
Luo,
Lei
Chen,
M.
Ye,
Jianan
Huang,
X.
Zhi,
Yiping
Zhang,
Q.
Xiu,
Jun
Ma,
C.
You
(2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
The Lancet. Oncology, 12 8
-
N.
Roche,
H.
Reddel,
Richard
Martin,
G.
Brusselle,
A.
Papi,
M.
Thomas,
Dirjke
Postma,
V.
Thomas,
C.
Rand,
A.
Chisholm,
David
Price
(2014)
Quality standards for real-world research. Focus on observational database studies of comparative effectiveness.
Annals of the American Thoracic Society, 11 Suppl 2
-
S.
Ou,
Siraj
Ali,
J.
Bogart,
S.
Graziano,
M.
Mix,
J.
Ross,
V.
Miller,
A.
Schrock
(2018)
Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).
Journal of Clinical Oncology, 36
-
T.
Mok,
Ying
Cheng,
Xiang-dong
Zhou,
K.
Lee,
K.
Nakagawa,
S.
Niho,
M.
Lee,
R.
Linke,
R.
Rosell,
J.
Corral,
M.
Migliorino,
A.
Płużański,
E.
Sbar,
Tao
Wang,
Jane
White,
Yi-long
Wu
(2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 22
-
J.
Yang,
L.
Sequist,
Sarayut
Geater,
C.
Tsai,
T.
Mok,
M.
Schuler,
N.
Yamamoto,
Chong-Jen
Yu,
S.
Ou,
Caicun
Zhou,
D.
Massey,
V.
Zazulina,
Yi-long
Wu
(2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
The Lancet. Oncology, 16 7
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Yi-Cheng
Shen,
G.
Tseng,
Chih-Yeh
Tu,
Wei-Chun
Chen,
Wei-Chih
Liao,
Wei-Cheng
Chen,
Chia-Hsiang
Li,
Hung-Jen
Chen,
T.
Hsia
(2017)
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Lung cancer, 110
-
Satoshi
Watanabe,
Y.
Minegishi,
H.
Yoshizawa,
M.
Maemondo,
A.
Inoue,
S.
Sugawara,
H.
Isobe,
M.
Harada,
Y.
Ishii,
A.
Gemma,
K.
Hagiwara,
K.
Kobayashi
(2014)
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Journal of Thoracic Oncology, 9
-
J.
Yang,
M.
Ahn,
Dong-Wan
Kim,
S.
Ramalingam,
L.
Sequist,
W.
Su,
Sang-We
Kim,
Joo‐Hang
Kim,
D.
Planchard,
E.
Felip,
F.
Blackhall,
D.
Haggstrom,
K.
Yoh,
S.
Novello,
K.
Gold,
T.
Hirashima,
Chia‐Chi
Lin,
H.
Mann,
M.
Cantarini,
S.
Ghiorghiu,
P.
Jänne
(2017)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 12
-
D.
Fujimoto,
T.
Yokoyama,
H.
Yoshioka,
Y.
Demura,
K.
Hirano,
T.
Kawai,
Ryogo
Kagami,
T.
Ishida,
K.
Tomii,
M.
Akai,
M.
Hirabayashi,
T.
Nishimura,
Y.
Nakahara,
Y.
Kim,
K.
Yoshimura,
T.
Hirai
(2017)
465PA phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Annals of Oncology, 28
-
Shang-Gin
Wu,
Yi-nan
Liu,
Meng-Feng
Tsai,
Yih-Leong
Chang,
Chong-Jen
Yu,
Pan‐Chyr
Yang,
J.
Yang,
Yueh-Feng
Wen,
J.
Shih
(2016)
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Oncotarget, 7
-
S-HI
Ou,
SM
Ali,
J
Bogart
(2018)
Characterization of 1,233 NSCLCs with
non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling
(CGP)
J Clin Oncol, 36
-
S.
Khozin,
G.
Blumenthal,
R.
Pazdur
(2017)
Real-world Data for Clinical Evidence Generation in Oncology.
Journal of the National Cancer Institute, 109 11
-
T.
Reungwetwattana,
K.
Nakagawa,
B.
Cho,
M.
Cobo,
E.
Cho,
A.
Bertolini,
S.
Bohnet,
Caicun
Zhou,
K.
Lee,
N.
Nogami,
I.
Okamoto,
N.
Leighl,
R.
Hodge,
A.
McKeown,
Andrew
Brown,
Y.
Rukazenkov,
S.
Ramalingam,
J.
Vansteenkiste
(2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
MJ
Hochmair,
A
Buder,
S
Schwab
Liquid-biopsy-based identification of EGFR T790M
mutation-mediated resistance to afatinib treatment in patients with advanced
EGFR mutation-positive NSCLC, and subsequent response to
osimertinib
Target Oncol
-
Yongjian
Wu,
H.
Tu,
J.
Feng,
M.
Shi,
J.
Zhao,
Yu-zhao
Wang,
Jian-hua
Chang,
Jin
Wang,
Y.
Cheng,
J.
Zhu,
E.
Tan,
Kai
Li,
Y.
Zhang,
V.
Lee,
Cheng-Ta
Yang,
W.
Su,
D.
Lam,
B.
Srinivasa,
S.
Rajappa,
C.
Ho,
K.
Lam,
Yi
Hu,
S.
Bondarde,
X.
Liu,
D.
Huang,
K.
Pang,
C.
Zhou
(2018)
P1.01-98 A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions
Journal of Thoracic Oncology
-
Sheng-Kai
Liang,
Min-Shu
Hsieh,
Meng-Rui
Lee,
Li-Ta
Keng,
J.
Ko,
J.
Shih
(2017)
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Oncotarget, 8
-
Yuehua
Wu,
H.
Tu,
J.
Feng,
M.
Shi,
Jinxia
Zhao,
Yong
Wang,
Jian-hua
Chang,
Jin
Wang,
Y.
Cheng,
J.
Zhu,
E.
Tan,
Kai
Li,
Y.
Zhang,
V.
Lee,
Cheng-Ta
Yang,
W.
Su,
C.
Lam,
B.
Srinivasa,
S.
Rajappa,
C.
Ho,
K.
Lam,
Yi
Hu,
S.
Bondarde,
X.
Liu,
J.
Fan,
D.
Kuo,
K.
Pang,
C.
Zhou
(2017)
P3.01-036 A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
Journal of Thoracic Oncology, 12
-
S.
Kohsaka,
M.
Nagano,
Toshihide
Ueno,
Y.
Suehara,
T.
Hayashi,
N.
Shimada,
Kazuhisa
Takahashi,
Kenji
Suzuki,
K.
Takamochi,
F.
Takahashi,
H.
Mano
(2017)
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
Science Translational Medicine, 9
-
Yoshihisa
Kobayashi,
T.
Mitsudomi
(2016)
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Cancer Science, 107
-
Qianqian
Zhu,
Ya-nan
Sun,
Yingying
Cui,
K.
Ye,
Chengliang
Yang,
Daoke
Yang,
Jie
Ma,
Xiao
Liu,
Jinming
Yu,
H.
Ge
(2017)
Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)
Oncotarget, 8
-
L
Paz-Ares,
EH
Tan,
K
O’Byrne
(2017)
Afatinib versus gefitinib in patients with EGFR
mutation-positive advanced non-small-cell lung cancer: overall survival data
from the phase IIb LUX-Lung 7 trial
Ann
Oncol, 28
-
J.
Yang,
L.
Sequist,
C.
Zhou,
M.
Schuler,
Sarayut
Geater,
T.
Mok,
C.
Hu,
N.
Yamamoto,
J.
Feng,
K.
O'Byrne,
S.
Lu,
V.
Hirsh,
Y.
Huang,
M.
Sebastian,
I.
Okamoto,
N.
Dickgreber,
R.
Shah,
A.
Märten,
D.
Massey,
S.
Wind,
Y.
Wu
(2016)
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 11
-
LV
Sequist,
YL
Wu,
M
Schuler
(2017)
Subsequent therapies post-afatinib among
patients with EGFR mutation-positive NSCLC in LUX-Lung (LL) 3, 6 and
7
Ann Oncol, 28
-
T.
Mok,
Yi-long
Wu,
M.
Ahn,
M.
Garassino,
H.
Kim,
S.
Ramalingam,
F.
Shepherd,
Yong
He,
H.
Akamatsu,
W.
Theelen,
C.
Lee,
M.
Sebastian,
A.
Templeton,
H.
Mann,
M.
Marotti,
S.
Ghiorghiu,
V.
Papadimitrakopoulou
(2017)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
The New England Journal of Medicine, 376
-
A.
Fujiwara,
Masamichi
Yoshida,
H.
Fujimoto,
H.
Nakahara,
K.
Ito,
Kota
Nishihama,
T.
Yasuma,
O.
Hataji,
O.
Taguchi,
C.
D'Alessandro-Gabazza,
E.
Gabazza,
Tetsu
Kobayashi
(2018)
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Oncology research, 26 7
-
A.
Tamiya,
M.
Tamiya,
T.
Nishihara,
T.
Shiroyama,
K.
Nakao,
T.
Tsuji,
N.
Takeuchi,
S.
Isa,
N.
Omachi,
N.
Okamoto,
Hidekazu
Suzuki,
K.
Okishio,
A.
Iwazaki,
Kimie
Imai,
T.
Hirashima,
S.
Atagi
(2017)
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Anticancer research, 37 8
-
D.
Lakdawalla,
J.
Shafrin,
N.
Hou,
D.
Peneva,
S.
Vine,
Jinhee
Park,
Jie
Zhang,
R.
Brookmeyer,
R.
Figlin
(2017)
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 20 7
-
Y
Kim,
SH
Lee,
JS
Ahn
Efficacy and safety of afatinib for EGFR-mutant
non-small cell lung cancer, compared with gefitinib or
erlotinib
Cancer Res Treat
-
Yi-long
Wu,
Ying
Cheng,
Xiang-dong
Zhou,
K.
Lee,
K.
Nakagawa,
S.
Niho,
F.
Tsuji,
R.
Linke,
R.
Rosell,
J.
Corral,
M.
Migliorino,
A.
Płużański,
E.
Sbar,
Tao
Wang,
Jane
White,
S.
Nadanaciva,
R.
Sandin,
T.
Mok
(2017)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
The Lancet. Oncology, 18 11
-
D
Fujimoto,
T
Yokoyama,
H
Yoshioka
(2017)
A phase II study of low-dose afatinib as
first-line treatment in patients with EGFR mutation-positive non-small-cell
lung cancer (KTORG1402)
Ann Oncol, 28
-
LV
Sequist,
BA
Waltman,
D
Dias-Santagata
(2011)
Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors
Sci
Transl Med, 3
-
Yuankai
Shi,
Lvhua
Wang,
B.
Han,
W.
Li,
P.
Yu,
Yunpeng
Liu,
C.
Ding,
X.
Song,
Z.
Ma,
X.
Ren,
J.
Feng,
H.
Zhang,
Gongyan
Chen,
Xiaohong
Han,
N.
Wu,
C.
Yao,
Ying-qiu
Song,
S.
Zhang,
W.
Song,
Xiaoqing
Liu,
S.
Zhao,
Y.
Lin,
X.
Ye,
Kai
Li,
Y.
Shu,
L.
Ding,
F.
Tan,
Yan
Sun
(2017)
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
Annals of Oncology, 28
-
Donghui
Li,
Jeffrey
Morris,
Jun
Liu,
Manal
Hassan,
R.
Day,
Melissa
Bondy,
J.
Abbruzzese
(2009)
F1000 highlights
Asia‐Pacific Journal of Clinical Oncology, 5
-
C.
Langer,
M.
Mehta
(2005)
Current management of brain metastases, with a focus on systemic options.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
-
TS
Mok,
YL
Wu,
S
Thongprasert
(2009)
Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma
N Engl J Med, 361
-
WL
Tan,
QS
Ng,
C
Lim
(2018)
Influence of afatinib dose on outcomes of
advanced EGFR-mutant NSCLC patients with brain metastases
BMC Cancer, 18
-
YT
Lin,
JS
Chen,
WY
Liao
Clinical outcomes and secondary epidermal growth
factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib
and afatinib-treated non-small cell lung cancer patients with activating
EGFR mutations
Int J Cancer
-
Y
Wu,
H
Tu,
J
Feng
(2017)
P3.01–036 A phase IIIb open-label, single-arm
study of afatinib in EGFR TKI-naïve patients with EGFRm + NSCLC: an interim
analysis
J Thorac Oncol, 12
-
T
Reungwetwattana,
K
Nakagawa,
BC
Cho
(2018)
CNS response to osimertinib versus standard
epidermal growth factor receptor tyrosine kinase inhibitors in patients with
untreated EGFR-mutated advanced non-small-cell lung cancer
study
J Clin Oncol, 36
-
SC
Lau,
N
Chooback,
CC
Ho
(2017)
Differential outcomes between first and second
generation TKIs in patients with activating EGFR mutations in
NSCLC
J Thorac Oncol, 12
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
(2017)
First-line afatinib for non-small-cell lung cancer in realworld practice
-
S.
Lau,
N.
Chooback,
C.
Ho,
B.
Melosky
(2017)
P3.01-015 Differential Outcomes between First and Second Generation TKIs in Patients with Activating EGFR Mutations in NSCLC
Journal of Thoracic Oncology, 12
-
祥久
小林
(2017)
EGFR Exon 18 Mutations in Lung Cancer:Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
-
Y.
Wu,
C.
Zhou,
C.
Liam,
G.
Wu,
X.
Liu,
Z.
Zhong,
S.
Lu,
Y.
Cheng,
B.
Han,
L.
Chen,
C.
Huang,
S.
Qin,
Y.
Zhu,
H.
Pan,
H.
Liang,
E.
Li,
G.
Jiang,
S.
How,
M.
Fernando,
Y.
Zhang,
F.
Xia,
Y.
Zuo
(2015)
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 9
-
Yoshihisa
Kobayashi,
Y.
Togashi,
Y.
Yatabe,
H.
Mizuuchi,
Park
Jangchul,
C.
Kondo,
M.
Shimoji,
Katsuaki
Sato,
K.
Suda,
K.
Tomizawa,
T.
Takemoto,
T.
Hida,
K.
Nishio,
T.
Mitsudomi
(2015)
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Clinical Cancer Research, 21
-
Yi-long
Wu,
Caicun
Zhou,
Cheng-ping
Hu,
Jifeng
Feng,
Shun
Lu,
Yunchao
Huang,
Wei
Li,
M.
Hou,
Jianhua
Shi,
K.
Lee,
Chongrui
Xu,
D.
Massey,
Miyoung
Kim,
Yang
Shi,
Sarayut
Geater
(2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
The Lancet. Oncology, 15 2
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
C.
Tu,
Chuan-Mu
Chen,
Wei-Chih
Liao,
Biing-Ru
Wu,
Chih-Yu
Chen,
Wei-Chun
Chen,
T.
Hsia,
W.
Cheng,
Chia-Hung
Chen
(2018)
Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
Oncotarget, 9
-
Rachel
Sherman,
S.
Anderson,
G.
Pan,
Gerry
Gray,
T.
Gross,
Nina
Hunter,
L.
LaVange,
D.
Marinac-Dabic,
P.
Marks,
Melissa
Robb,
J.
Shuren,
R.
Temple,
J.
Woodcock,
L.
Yue*,
R.
Califf
(2016)
Real-World Evidence - What Is It and What Can It Tell Us?
The New England journal of medicine, 375 23
-
M.
Hochmair,
A.
Buder,
S.
Schwab,
O.
Burghuber,
H.
Prosch,
W.
Hilbe,
A.
Cseh,
R.
Fritz,
M.
Filipits
(2018)
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Targeted Oncology, 14
-
V.
Noronha,
A.
Joshi,
Anant
Gokarn,
Vibhor
Sharma,
V.
Patil,
A.
Janu,
N.
Purandare,
A.
Chougule,
N.
Jambhekar,
K.
Prabhash
(2014)
The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
Chemotherapy Research and Practice, 2014
-
Keunchil
Park,
E.
Tan,
K.
O'Byrne,
Li
Zhang,
M.
Boyer,
T.
Mok,
V.
Hirsh,
J.
Yang,
K.
Lee,
Shun
Lu,
Yuankai
Shi,
Sang-We
Kim,
J.
Laskin,
Dong-Wan
Kim,
C.
Arvis,
K.
Kölbeck,
S.
Laurie,
C.
Tsai,
M.
Shahidi,
Miyoung
Kim,
D.
Massey,
V.
Zazulina,
L.
Paz-Ares
(2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
The Lancet. Oncology, 17 5
-
J.
Skřičková,
R.
Chloupková,
Z.
Bortlíček,
M.
Pešek,
V.
Kolek,
K.
Hejduk,
L.
Koubková,
M.
Černovská,
J.
Krejci,
M.
Zemanova,
L.
Havel,
J.
Roubec,
M.
Hrnčiarik,
F.
Salajka,
H.
Čoupková,
M.
Šatánková,
A.
Benejová,
I.
Grygárková,
P.
Opálka,
D.
Sixtová
(2017)
P2.03-023 Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
Journal of Thoracic Oncology, 12
-
Yin-duo
Zeng,
Li
Zhang,
H.
Liao,
Ying-ying
Liang,
Fei
Xu,
Jun-ling
Liu,
Xiao‐xiao
Dinglin,
Likun
Chen
(2012)
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Asian Pacific journal of cancer prevention : APJCP, 13 3
-
SS
Ramalingam,
Y
Cheng,
C
Zhou
(2018)
Mechanisms of acquired resistance to first-line
osimertinib: Preliminary data from the phase III FLAURA
study
Ann Oncol, 29
-
L.
Paz-Ares,
E.
Tan,
K.
O'Byrne,
L.
Zhang,
V.
Hirsh,
M.
Boyer,
J.
Yang,
T.
Mok,
K.
Lee,
S.
Lu,
Y.
Shi,
D.
Lee,
J.
Laskin,
D-W.
Kim,
S.
Laurie,
K.
Kölbeck,
J.
Fan,
N.
Dodd,
A.
Märten,
K.
Park
(2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Annals of oncology : official journal of the European Society for Medical Oncology
-
F.
Kuan,
Shih-Hong
Li,
Chih-Liang
Wang,
Meng-Hung
Lin,
Y.
Tsai,
Cheng-Ta
Yang
(2016)
Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
Oncotarget, 8